GDF-15 and Early Outcomes After LVAD Implantation

Association of Preoperative GDF-15 Levels With Early Postoperative Outcomes and Mortality After LVAD Implantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07497308

Acronym

LVAD-GDF15

Enrollment

Registered

2026-03-27

Start date

2026-02-04

Completion date

2026-12-23

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Heart Failure, Left Ventricular Assist Device Implantation

Keywords

Left Ventricular Assist Device, GDF-15, Postoperative Outcomes, Early Mortality

Brief summary

This observational study aims to investigate the association between preoperative GDF-15 levels and early postoperative outcomes in patients undergoing left ventricular assist device (LVAD) implantation. The study will evaluate whether elevated preoperative GDF-15 levels are associated with adverse early outcomes, including postoperative complications and mortality. The findings may help improve preoperative risk assessment and identify high-risk patients before LVAD implantation.

Detailed description

Left ventricular assist device (LVAD) implantation is an established treatment option for patients with advanced heart failure. However, these patients remain at substantial risk for early postoperative morbidity and mortality. Identification of preoperative biomarkers associated with adverse outcomes may improve perioperative risk assessment and support clinical decision-making. Growth differentiation factor-15 (GDF-15) is a biomarker related to inflammation, oxidative stress, and cardiovascular injury, and may have prognostic value in high-risk cardiac populations. This observational study will investigate the relationship between preoperative GDF-15 levels and early postoperative outcomes in patients undergoing LVAD implantation. Preoperative serum GDF-15 levels will be evaluated for their association with early postoperative complications, mortality, and other short-term clinical outcomes. The study is intended to clarify whether GDF-15 can serve as a useful biomarker for identifying patients at increased risk before LVAD implantation. Improved preoperative risk stratification may help optimize perioperative management and patient selection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Adults aged 18 years and older Patients with advanced heart failure undergoing LVAD implantation Availability of preoperative GDF-15 measurement Ability to provide written informed consent or consent provided by a legally authorized representative, according to local regulations -

Exclusion criteria

Age under 18 years Active infection Active malignancy Severe hepatic failure Missing study data Refusal to participate \-

Design outcomes

Primary

Measure	Time frame	Description
Early Postoperative Mortality	30 days after LVAD implantation	Mortality occurring during the early postoperative period after LVAD implantation

Secondary

Measure	Time frame	Description
Postoperative Complications	Up to 30 days after LVAD implantation	Occurrence of early postoperative complications after LVAD implantatio

Countries

Turkey (Türkiye)

Contacts

CONTACTemel gündüz, md

dregunduz@hotmail.com+902422496000

Outcome results